Evidence map›Paper›PMID 38688590›Full record

ArticleIn vivo (Athens, Greece)

The Clinical Impact of the Pretreatment Albumin to Fibrinogen Ratio in Esophageal Cancer Patients Who Receive Curative Treatment.

Toru Aoyama, Yukio Maezawa, Itaru Hashimoto, Kentaro Hara, Keisuke Kazama, Keisuke Komori, Aya Kato, Kazuki Otani, Ayako Tamagawa, Haruhiko Cho and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Toru Aoyama *Department of Surgery, Yokohama City University, Yokohama, Japan; t-aoyama@lilac.plala.or.jp.
Yukio Maezawa *Department of Surgery, Yokohama City University, Yokohama, Japan.
Itaru HashimotoDepartment of Surgery, Yokohama City University, Yokohama, Japan; itarum1n1@hotmail.com.
Kentaro HaraDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Keisuke KazamaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Keisuke KomoriDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Aya KatoDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Kazuki OtaniDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Ayako TamagawaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Haruhiko ChoDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Junya MoritaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Shinnosuke KawaharaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Mie TanabeDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Takashi OshimaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Aya SaitoDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Norio YukawaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Yasushi RinoDepartment of Surgery, Yokohama City University, Yokohama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimThe albumin to fibrinogen ratio (AFR) has been identified as a promising prognostic marker for some malignancies. The aim of the present study was to evaluate the clinical impact of AFR in esophageal cancer patients who received curative resection. PATIENTS AND

methodsThe present study included 123 patients who underwent curative treatment for esophageal cancer between 2005 and 2020. The prognosis and clinicopathological parameters were compared between patients with high and low AFRs.

resultsThe overall survival (OS) stratified by each clinical factor was compared using the log-rank test, and a significant difference was observed when using a pretreatment AFR of 1.23. When comparing the patient backgrounds between the high-AFR (AFR ≥12.3) and low-AFR (AFR<12.3) groups, significant differences were noted in the pathological T status. The high-AFR group had significantly higher OS rates at 3 years (70.8%) and 5 years (59.3%) after surgery in comparison to the low-AFR group (46.6% and 37.4%, respectively). Univariate and multivariate analyses for OS showed that the AFR was a significant prognostic factor. In addition, when comparing the site of first recurrence, a marginally significant difference was noted in hematological recurrence.

conclusionThe AFR is a significant risk factor in patients with esophageal cancer, holding promise as a valuable prognostic factor.

Indexed as

Esophageal NeoplasmsFibrinogenAdultAgedAged, 80 and overBiomarkers, TumorFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPrognosisSerum AlbuminBiomarkers, TumorFibrinogenSerum AlbuminalbuminEsophageal cancerfibrinogensurvival

Identifiers

PMID38688590
PMCPMC11059917

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.